Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.

In comparison, cells treated with P2short only exhibited a slight trend to accumulate in G1 after 24 h following treatment with either 1 or 10 μM P2short, compared to mock-treated cells, ( Figure 5 F ).

also in 3,900 other papers